Tag: Olumiant

February 14, 2017 Off

European Commission approves Lilly’s and Incyte’s rheumatoid arthritis drug

By Dino Mustafić

Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).